Literature DB >> 33284430

Identification of Critical Transcriptomic Signaling Pathways in Patients with H Syndrome and Rosai-Dorfman Disease.

Samuel Lara-Reyna1,2, James A Poulter1,2, Elton J R Vasconcelos3, Mark Kacar1,4, Michael F McDermott1, Reuben Tooze5, Rainer Doffinger6, Sinisa Savic7,8.   

Abstract

Biallelic mutations in SLC29A3 cause histiocytosis-lymphadenopathy plus syndrome, also known as H syndrome (HS). HS is a complex disorder, with ~ 25% of patients developing autoinflammatory complications consisting of unexplained fevers, persistently elevated inflammatory markers, and unusual lymphadenopathies, with infiltrating CD68+, S100+, and CD1a- histiocytes, resembling the immunophenotype found in Rosai-Dorfman disease (RDD). We investigated the transcriptomic profiles of monocytes, non-activated (M0), classically activated (M1), and alternatively activated macrophages (M2) in two patients with HS, one without autoinflammatory (HS1) and one with autoinflammatory complications (HS2). RNA sequencing revealed a dysregulated transcriptomic profile in both HS patients compared to healthy controls (HC). HS2, when compared to HS1, had several differentially expressed genes, including genes associated with lymphocytic-histiocytic predominance (e.g. NINL) and chronic immune activation (e.g. B2M). The transcriptomic and cytokine profiles of HS patients were comparable to patients with SAID with high levels of TNF. SERPINA1 gene expression was found to be upregulated in all patients studied. Moreover, higher levels of IFNγ were found in the serum of both HS patients when compared to HC. Gene ontology (GO) enrichment analysis of the DEGs in HS patients revealed the terms "type I IFN," "IFNγ signaling pathway," and "immune responses" as the top 3 most significant terms for monocytes. Gene expression analysis of lymph node biopsies from sporadic and H syndrome-associated RDD suggests common underlying pathological process. In conclusion, monocytes and macrophages from both HS patients showed transcriptomic profiles similar to SAIDs and also uniquely upregulated IFNγ signature. These findings may help find better therapeutic options for this rare disorder.

Entities:  

Keywords:  H syndrome; interferon gamma; systemic autoinflammatory disease

Mesh:

Substances:

Year:  2020        PMID: 33284430      PMCID: PMC7858559          DOI: 10.1007/s10875-020-00932-1

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  60 in total

1.  Type I interferonopathies: a novel set of inborn errors of immunity.

Authors:  Yanick J Crow
Journal:  Ann N Y Acad Sci       Date:  2011-11       Impact factor: 5.691

2.  Nomenclature of monocytes and dendritic cells in blood.

Authors:  Loems Ziegler-Heitbrock; Petronela Ancuta; Suzanne Crowe; Marc Dalod; Veronika Grau; Derek N Hart; Pieter J M Leenen; Yong-Jun Liu; Gordon MacPherson; Gwendalyn J Randolph; Juergen Scherberich; Juergen Schmitz; Ken Shortman; Silvano Sozzani; Herbert Strobl; Marek Zembala; Jonathan M Austyn; Manfred B Lutz
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

3.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

Review 4.  Molecular interactions and functions of IL-32.

Authors:  Kristin Roseth Aass; Martin H Kastnes; Therese Standal
Journal:  J Leukoc Biol       Date:  2020-09-01       Impact factor: 4.962

Review 5.  Moving towards a systems-based classification of innate immune-mediated diseases.

Authors:  Sinisa Savic; Emily A Caseley; Michael F McDermott
Journal:  Nat Rev Rheumatol       Date:  2020-02-27       Impact factor: 20.543

6.  Equilibrative nucleoside transporter 3 deficiency perturbs lysosome function and macrophage homeostasis.

Authors:  Chia-Lin Hsu; Weiyu Lin; Dhaya Seshasayee; Yung-Hsiang Chen; Xiao Ding; Zhonghua Lin; Eric Suto; Zhiyu Huang; Wyne P Lee; Hyunjoo Park; Min Xu; Mei Sun; Linda Rangell; Jeff L Lutman; Sheila Ulufatu; Eric Stefanich; Cecile Chalouni; Meredith Sagolla; Lauri Diehl; Paul Fielder; Brian Dean; Mercedesz Balazs; Flavius Martin
Journal:  Science       Date:  2011-12-15       Impact factor: 47.728

Review 7.  Beta2-microglobulin: emerging as a promising cancer therapeutic target.

Authors:  Chunmeng Shi; Ying Zhu; Yongping Su; Leland W K Chung; Tianmin Cheng
Journal:  Drug Discov Today       Date:  2008-12-26       Impact factor: 7.851

8.  Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.

Authors:  Franco Locatelli; Michael B Jordan; Carl Allen; Simone Cesaro; Carmelo Rizzari; Anupama Rao; Barbara Degar; Timothy P Garrington; Julian Sevilla; Maria-Caterina Putti; Franca Fagioli; Martina Ahlmann; Jose-Luis Dapena Diaz; Michael Henry; Fabrizio De Benedetti; Alexei Grom; Genevieve Lapeyre; Philippe Jacqmin; Maria Ballabio; Cristina de Min
Journal:  N Engl J Med       Date:  2020-05-07       Impact factor: 91.245

Review 9.  Common and biased signaling pathways of the chemokine receptor CCR7 elicited by its ligands CCL19 and CCL21 in leukocytes.

Authors:  Mark A Hauser; Daniel F Legler
Journal:  J Leukoc Biol       Date:  2016-01-04       Impact factor: 4.962

Review 10.  The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions.

Authors:  Sabina Janciauskiene; Sabine Wrenger; Stephan Immenschuh; Beata Olejnicka; Timm Greulich; Tobias Welte; Joanna Chorostowska-Wynimko
Journal:  Front Pharmacol       Date:  2018-04-17       Impact factor: 5.810

View more
  1 in total

Review 1.  Inborn Errors of Nucleoside Transporter (NT)-Encoding Genes (SLC28 and SLC29).

Authors:  Marçal Pastor-Anglada; Aida Mata-Ventosa; Sandra Pérez-Torras
Journal:  Int J Mol Sci       Date:  2022-08-07       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.